ATT001 / ATD001
ATT001 is a novel iodine radiolabelled PARP inhibitor (rPARPi) which will soon enter clinical trials toward the development of this exciting product as a targeted radionuclide therapy.
ATD001 is a novel fluorine-18 radiolabelled PARP inhibitor (rPARPi) currently in Phase I clinical trials at Memorial Sloan Kettering Cancer Center. The first clinical study for ATD001 in head and neck cancers completed recruitment in May 2019 and data was subsequently published in the following peer-reviewed publication: Schöder et al, 2020.
The first clinical study for ATD001 in brain tumours finished recruiting early this year and the data is now available in the following peer reviewed publication: Young et al, 2020.